We show that routine GATA2 IHC identifies 33% of FIGO stage I USCs with high GATA2 expression (GATA2hi) and that patients with GATA2hi USCs do not experience cancer recurrence after hysterectomy, even when adjuvant therapy is omitted. Here, GATA2 is linked to cancer.